Why Edwards Lifesciences (EW) Is Back On Investor Radar
With no single headline event driving attention today, Edwards Lifesciences (EW) is drawing interest for its recent share performance and current fundamentals. This is inviting a closer look at how the stock now stacks up.
See our latest analysis for Edwards Lifesciences.
The recent 1-day share price return of 3.10% and 7-day share price return of 5.41% suggest short term momentum is building. The 1-year total shareholder return of 14.39% contrasts with a weaker 5-year total shareholder return, which has declined 10.55%.
If this kind of move has you checking what else is setting up, it could be a good moment to look at 34 healthcare AI stocks
Edwards Lifesciences shares now sit near $85.78, with metrics like an intrinsic value estimate suggesting a modest 4% discount and analyst targets implying more. So are you looking at underappreciated upside, or is the market already pricing in future growth?
Most Popular Narrative: 12% Undervalued
Edwards Lifesciences' most followed narrative points to a fair value of about $97.15 versus the last close at $85.78, which is drawing attention to what assumptions sit underneath that gap.
The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future. The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.
Want to see what kind of revenue trajectory and margin profile that scenario is built on? The key ingredients are layered growth assumptions, rising profitability and a valuation multiple that stays above the broader medical equipment sector.
Result: Fair Value of $97.15 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there is still a risk that tariffs and higher R&D and investment spending compress margins, or that competition in markets like Japan slows TAVR procedure growth.
Find out about the key risks to this Edwards Lifesciences narrative.
Another Way To Look At Valuation
While the narrative and fair value estimate point to Edwards Lifesciences trading about 3.9% below an intrinsic value of $89.26, the current P/E of 45.9x tells a different story. It sits well above both the industry average of 24.5x and a fair ratio of 29.2x. This suggests investors are already paying a heavy premium for future earnings and leaving less room for error if expectations shift.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Seeing both optimism and concern in this story, it makes sense to move quickly, review the full picture, and judge the balance for yourself with 2 key rewards and 3 important warning signs.
Looking for more investment ideas?
If Edwards Lifesciences has caught your attention, do not stop here. Use the Simply Wall Street Screener to uncover fresh opportunities that match your style.
- Target steady cash returns by checking out 10 dividend fortresses that focus on income potential with higher yields.
- Spot potential bargains early by scanning screener containing 21 high quality undiscovered gems before they are widely followed.
- Keep risk in check by focusing on 67 resilient stocks with low risk scores that score well on resilience and balance sheet strength.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com